NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences Corp (NYSE:EW) posted its quarterly earnings results on Wednesday, October, 23rd. The medical research company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.19. The medical research company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The firm's quarterly revenue was up 20.7% compared to the same quarter last year. During the same period last year, the company earned $1.07 EPS. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, December, 5th. The company provided EPS guidance of $6.05-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.98. The company issued revenue guidance of $4.5-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

19 equities research analysts have issued 1 year price objectives for Edwards Lifesciences' stock. Their forecasts range from $159.00 to $285.00. On average, they expect Edwards Lifesciences' stock price to reach $239.83 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

News articles about EW stock have trended positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Edwards Lifesciences.

Edwards Lifesciences saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,350,000 shares, an increase of 18.7% from the December 15th total of 1,980,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 2.0 days. Approximately 1.1% of the company's shares are short sold. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Home Depot (HD), Visa (V), Walt Disney (DIS), Mastercard (MA), UnitedHealth Group (UNH), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Chicago Capital LLC (0.07%), Scout Investments Inc. (0.06%), Country Trust Bank (0.05%), Calamos Advisors LLC (0.04%), Gateway Investment Advisers LLC (0.04%) and Peregrine Capital Management LLC (0.04%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Country Trust Bank, Gateway Investment Advisers LLC, Tributary Capital Management LLC, OLD National Bancorp IN, State of Alaska Department of Revenue, Chicago Capital LLC and Artemis Investment Management LLP. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Scout Investments Inc., Tuttle Tactical Management, TrimTabs Asset Management LLC, Diversified Trust Co, DNB Asset Management AS, FormulaFolio Investments LLC and Cozad Asset Management Inc.. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $238.58.

Edwards Lifesciences has a market capitalization of $49.76 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.View Additional Information About Edwards Lifesciences.

The official website for Edwards Lifesciences is http://www.edwards.com/.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]